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AbstrAct
Introduction Out-of-hospital cardiac arrest (OHCA) 
has an annual incidence of approximately 60 000 in the 
UK. Less than 10% of those who receive resuscitation 
survive to hospital discharge. For OHCA of a presumed 
cardiac cause, the optimal antiplatelet therapy is 
currently unknown. Previous studies indicate that 
a procoagulopathic state exists postcardiac arrest 
which may contribute to the formation of thrombi 
and contribute to poor outcomes. However, the 
administration of antiplatelet therapies needs to be 
balanced against the increased risk of bleeding that 
these individuals face.
Methods and analysis This observational feasibility 
study will recruit 30 individuals who achieve return 
of spontaneous circulation post-OHCA, are admitted 
to a single tertiary centre over a 6-month period and 
meet Utstein cohort criteria (witnessed cardiac arrest, 
VF or pulseless VT and cardiac cause of arrest likely). 
Rotational thromboelastometry and platelet function 
assessment will be performed on hospital arrival, 
postemergency percutaneous coronary intervention 
(PCI) and 12 hours, 24 hours and 48 hours post-PCI. 
As a comparator, 30 individuals presenting to our 
institution with ST-segment elevation myocardial 
infarction and undergoing primary PCI will have the 
same blood sampling performed. Plasma samples will 
be retained and batch tested on completion of the study 
for levels of protein C, protein S, thrombin–antithrombin 
complex, thrombin, antithrombin, plasminogen activator 
inhibitor-1, plasmin–antiplasmin complex, d-dimer, 
platelet factor-4, P selectin, E selectin and prothrombin 
fragments 1 and 2. 30-day follow-up for complications 
will be undertaken.
Ethics and dissemination This study has been 
approved by the Wales REC 7Research Ethics 
Committee. The results will be submitted to peer-
reviewed medical journals and suitable national 
and international meetings. Results will be locally 
disseminated via our patient and public interest group.
Trial registration number Pre-results; 
ISRCTN34122839.
IntroductIon
It is estimated that 60 000 out-of-hospital 
cardiac arrests (OHCAs) occur in the UK 
each year, of which 31 000 have resuscitation 
commenced or continued by emergency 
medical services.1 Data from Ambulance 
Quality Indicator statistics demonstrate that 
the survival rate postcardiac arrest to hospital 
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Protocol
Strengths and limitations of this study
 ► The research site is a busy regional cardiac arrest 
and primary percutaneous coronary intervention 
centre, serving a population of 1 000 000.
 ► The study is supported by a multidisciplinary 
steering committee, with a strong track record of 
successfully delivering clinical trials in the relevant 
fields of emergency medicine, cardiology and 
platelet assessment.
 ► The rotational  thromboelastometry system is 
used currently as a research tool within the host 
institution, supported by experience in a wide range 
of platelet function techniques.
 ► This is an observational feasibility study with a 
relatively small sample size.
 ► Cardiac arrest is the end point of a number of 
pathological processes. Although the Utstein cohort 
are being selected to reduce heterogeneity, enrolled 
patients are likely to have different causes of cardiac 
arrest.
 ► No literature exists as to the size of the effect we 
are expecting with regard to platelet function over 
time; therefore, we have not been able to complete 
a power calculation.
 ► Volume of nasogastric aspirate measurement offers 
only indirect evidence of drug absorption.
group.bmj.com on August 24, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Skorko A, et al. BMJ Open 2017;7:e015663. doi:10.1136/bmjopen-2016-015663
Open Access 
discharge is around 8%, with regional variability within 
the UK from 6.7% to 9.4%.2 3 Due to the heterogeneous 
nature of OHCAs and difficulties in standardising data 
for publication, a uniform model was proposed by an 
international task force in 1991. The ‘Utstein compar-
ator cohort’ is an internationally agreed OHCA cohort 
comprising those who have OHCA of presumed cardiac 
origin, have a witnessed OHCA and ventricular fibrilla-
tion or ventricular tachycardia as the initial heart rhythm.4 
Within the UK in the period 2014–2015, this standardised 
subset of OHCAs achieved return of spontaneous circu-
lation (ROSC) in 49% of instances and the survival to 
hospital discharge was 26.3%.2 The Utstein group forms 
a small proportion of OHCA admissions, but are more 
representative of cardiogenic OHCA.
Cardiogenic OHCA results from myocardial isch-
aemia/infarction secondary to coronary artery occlusion, 
the extreme end of the acute coronary syndrome spec-
trum. The mainstay of treatment following OHCA due to 
coronary occlusion is twofold: rapid restoration of blood 
flow to the myocardium and instigation of neuroprotec-
tive mechanisms to minimise hypoxic brain injury.5
Throughout the UK a network of regional centres offers 
emergency percutaneous coronary intervention (PCI) 
and coronary stent insertion 24 hours a day to expedite 
restoration of blood flow. Following stent insertion, it is of 
utmost importance to ensure vessel patency and avoid the 
complication of in-stent thrombosis. To this end, admin-
istration of antiplatelet and antithrombotic therapies to 
suppress thrombus formation is vital.
In the context of OHCA, there is evidence to suggest 
that a prothrombotic tendency exists.6 Activation of 
thrombosis may help explain poorer outcomes, so the 
administration of antiplatelet drugs is potentially even 
more vital in this subset of patients.
However, a delicate balance exists between the risk 
of coronary thrombosis and the bleeding risk posed by 
potent platelet inhibitors, particularly in the context of 
a critically ill individual. Aspirin has been the traditional 
mainstay of therapy in these patients, but significant 
advances in the inhibition of platelet activity have occurred 
in recent years. Clopidogrel, a second-generation thien-
opyridine has been superseded by the third-generation 
drugs prasugrel and ticagrelor. These newer drugs are 
given in conjunction with aspirin after coronary stenting 
in a regimen known as dual antiplatelet therapy (DAPT).
Platelet inhibition by any of these oral drugs takes a 
period of time to become effective. In the acute phase, 
until these drugs can begin to exert an effect, the admin-
istration of intravenous platelet inhibitors, such as a 
glycoprotein IIb/IIIa receptor antagonist (abciximab, 
tirofiban or eptifibatide), direct thrombin inhibitors 
(bivalirudin) or intravenous ADP receptor antagonists 
(cangrelor) to prevent immediate thrombosis of stents is 
common during PCI.
Despite rapid PCI and DAPT, the vast majority of 
patients presenting after cardiac arrest will remain coma-
tose, so they will be admitted to an intensive care unit 
(ICU) for postresuscitation care. Until recently, a critical 
component of postcardiac arrest care was the neuropro-
tective strategy of therapeutic hypothermia (TH).7 This 
treatment involves cooling of the individual to a core body 
temperature of 32°C–34°C for 24–48 hours, followed by a 
subsequent gradual rewarming period. Since the publica-
tion of the 2013 paper by Nielsen et al the role of TH has 
become less clear and has been superseded by targeted 
temperature management (TTM) where temperature is 
controlled in the range of 33°C–36°C for 48–72 hours8. 
However, at present, equipoise exists as to whether TH 
or TTM is the superior neuroprotective strategy, so clini-
cians currently make an assessment of appropriateness 
on a case-by-case basis. Profound hypothermia has been 
shown to impair platelet activation and induce fibrino-
lysis, thus increasing the risk of bleeding. This becomes 
more profound at progressively lower temperatures.
Current understanding of the relative effectiveness of 
all antiplatelet drugs following OHCA and particularly 
in therapeutically cooled humans is limited. Evidence 
suggests that these patients have a greater rate of in-stent 
thrombosis, with rates of 10% reported.9 There are 
several recognised factors that specifically attenuate the 
effectiveness of DAPT in this population such as delayed 
administration, poor absorption, altered metabolism, 
multiorgan failure and the effect of TTM which may all 
impact on the efficacy of antiplatelet drugs.
In addition to the iatrogenic interventions that alter 
coagulation and platelet function, data suggest that a 
coagulopathy develops rapidly after cardiac arrest.6 Post-
cardiac arrest syndrome is a recognised proinflammatory 
state with upregulation of mediators such as TNFα and 
interleukin-6, both of which are known to cause platelet 
activation and thrombin production.10 This ultimately 
leads to a prothrombotic state and may explain why even 
after restoration of coronary flow outcomes remain poor 
post-OHCA.
In order to assess coagulation and platelet function 
dynamically, a number of techniques are available. One 
of the best established is rotational thrombolestom-
etry (ROTEM). This system uses the change in blood's 
viscoelastic properties during clot formation to infer the 
balance of coagulation, platelet function and fibrinolytic 
activity and displays the results in a graphical form. Its 
ability to map clot formation kinetics makes it an effec-
tive clinical tool for near patient assessment of dynamic 
coagulation. Using a variety of reagents, the system also 
makes it possible to appreciate the differential activities 
of the tissue factor (or extrinsic), contact activation (or 
intrinsic) and fibrin pathways of the coagulation system.
No single, ideal method for assessing dynamic platelet 
function currently exists. We will use a novel platelet 
module in conjunction with the ROTEM machine to 
assess P2Y12 and thrombin receptor function and so 
understand intrinsic platelet activity and subsequent 
impact of DAPT therapies. This new module uses the 
principle of impedance aggregometry but has the advan-
tage of being integrated into the ROTEM system and 
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Figure 1 Timeline of blood sampling in each study arm. OHCA, out-of-hospital cardiac arrest; PCI, percutaneous coronary 
intervention; STEMI, STE elevation myocardial infarction.
is more automated than other methods. We will under-
take an observational case-controlled feasibility study to 
describe the coagulopathy of cardiac arrest and how it 
changes over the first 48 hours following PCI, DAPT and 
TTM administration in Utstein comparator individuals 
admitted to a single UK tertiary cardiac arrest centre 
following OHCA. A second, control group will recruit 
those who are admitted to the same institution for emer-
gency primary PCI following acute myocardial infarction 
(STEMI, ST-segment elevation myocardial infarction).
Methods and analysIs
Primary study aim
The primary aim of this study is to assess and describe 
platelet function and coagulation at predefined time 
points, in Utstein cohort patients admitted to hospital 
with ROSC following OHCA.
An initial assessment of coagulation on admission will 
aim to identify what derangements of coagulation and 
platelet function occur postcardiac arrest prior to any 
pharmacological intervention. Subsequent changes in 
clotting and platelet function following PCI, administra-
tion of antiplatelet therapy, and during the participant’s 
ICU stay (with particular focus on the effect of tempera-
ture control strategies) will be described.
secondary study aims
This feasibility study will be used to establish a sound 
methodology for assessing coagulation and platelet 
function in participants admitted to our institution 
with ROSC following OHCA. The results will be used 
to generate research hypotheses regarding the optimal 
strategy for antiplatelet therapy in Utstein criteria post-
OHCA participants for assessment in future clinical trials. 
We will collect data to compare the rates of bleeding, 
blood transfusion and in-stent thrombosis within 30 days 
of admission between the OHCA and STEMI groups.
study population
All adult patients following OHCA who meet Utstein 
cohort criteria presenting to the Bristol Royal Infirmary 
in the 6-month period from September 2016 to February 
2017 will be eligible for enrolment into this study.
The ‘Utstein comparator cohort’ is an internationally 
agreed OHCA cohort comprising those who have OHCA 
of presumed cardiac origin, have a witnessed arrest and 
ventricular fibrillation or ventricular tachycardia as the 
initial heart rhythm.
Individuals who are pregnant will not be eligible for 
enrolment as platelet function is known to alter during 
pregnancy. Due to the ethical implications, individuals 
who are known to have dementia, or are detained under 
either the Mental Health Act or by Her Majesty’s Prison 
Service will not be eligible. Finally, individuals who it is 
deemed will not benefit from ICU admission will not be 
enrolled.
As a control group, individuals who present to the 
Bristol Royal Infirmary coronary catheter laboratory 
(CCL) for primary PCI as treatment for STEMI will be 
eligible. Individuals will not be eligible if they have expe-
rienced a period of cardiac arrest prior to admission, do 
not meet the ESC criteria for STEMI, are not offered 
primary or are undergoing rescue PCI. This group forms 
the most suitable control group as they experience the 
same underlying pathological process of coronary plaque 
rupture and occlusion and receive the same initial DAPT, 
but without subsequent ICU interventions.
study design
All OHCA and STEMI individuals will be screened at 
admission to our institution. Following confirmation 
of enrolment and verbal assent in the STEMI arm, two 
citrated blood samples will be taken immediately. These 
samples will be processed within 2 hours on the ROTEM 
delta and platelet modules. The remaining blood sample 
will be centrifuged and the plasma stored at −80°C.
Further blood sampling for ROTEM analysis will occur 
at the end of PCI and at 12 hours, 24 hours and 48 hours 
post-PCI (figure 1). On each occasion, two citrate samples 
will be taken and processed as described above. Due to 
the 24 hours nature of OHCA admissions, achieving 
blood sampling at all time points may prove challenging. 
Therefore, priority will be given to collecting samples at 
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time points 1, 4 and 5 in OHCA survivors and 1 and 4 in 
the STEMI cohort.
Basic demographic data will be collected about partic-
ipants in each study arm, including past medical and 
medication histories. Information will be recorded about 
the cardiac arrest itself and arrival time in ED. Events 
in the CCL will be documented (therapy undertaken, 
number and site of stents and any complications) as 
will the doses and timing of antiplatelet and anticoag-
ulant therapies administered. During the subsequent 
48 hours the following data will be recorded: arterial 
blood gas results, haemoglobin, haematocrit, platelet 
count, international normalised ratio (INR), activated 
partial thromboplastin time (APTT), creatinine, use of 
renal replacement therapy, 24 hourly fluid balance, body 
temperature and target temperature, antiplatelet thera-
pies given with timings recorded and any deviation from 
prescription. Doses of vasopressors and sedation will be 
recorded as will daily APACHE II and SOFA scores. Any 
instances of bleeding, blood product transfusion, return 
to CCL, or vomiting will be recorded on the standardised 
case record form (CRF). Volume of nasogastric aspirate 
will be documented as an indirect indicator of drug 
absorption in OHCA participants.
Complications occurring within the first 30 days 
(including but not limited to: bleeding, need for trans-
fusion, return to CCL for in-stent thrombosis or further 
PCI), length of ICU, coronary care unit (CCU) and total 
hospital stay as well as 30-day survival will all be recorded. 
Bleeding severity will be quantified using the Bleeding 
Academic Research Consortium scale. This scale as has 
been advocated by several authors for assessment of 
bleeding following cardiac events.11 Classification of 
post-PCI complications will follow the Academic Research 
Consortium recommended guidelines.12
Given the feasibility nature of this study, a screening 
log will be kept to identify the individuals who were not 
enrolled and the reasons for this.
outcome measures
The primary outcome measure will be a description of 
ROTEM coagulation and platelet parameters following 
OHCA in the Utstein comparator cohort, from admission 
to 48 hours post-PCI. Coagulation and platelet function 
will be correlated with the data gathered to generate 
hypotheses regarding baseline coagulation and platelet 
function in OHCA participants and to what extent these 
are influenced by the medications administered and core 
body temperature. The same analysis will be undertaken 
in the control group of participants undergoing treat-
ment for STEMI who we anticipate receive comparable 
DAPT therapy without the subsequent ICU interventions.
data analysis plan
Data will be collected from medical notes and entered 
onto a CRF before being inputted into a predesigned, 
password protected excel spreadsheet. A 10% sample 
of CRFs will be reviewed by another researcher against 
medical notes to ensure data validity and accuracy of data 
entry.
Data will be analysed on an intention-to-treat basis 
to examine; choice of DAPT administered, timing of 
administration (pre-PCI, at PCI, post-PCI), preadmission 
exposure to antiplatelet therapy, degree of absorption of 
drug (as inferred from NG aspirates) and temperature 
management strategy in the OHCA group.
To track the platelet function and investigate its asso-
ciation with events such as DAPT administration and 
TTM, graphs will be used in the first instance. The results 
of platelet function and coagulation assessment will be 
plotted against time for all participants with different 
coloured markers for those in the two cohorts, for those 
before and after the administration of anticoagulants 
and those who have experienced bleeding events. This 
graphical representation will allow an understanding of 
the data, its limitations and its strengths. Natural logs of 
platelet function will be used rather than raw platelet 
function if the graphs show that there is more variability 
with high values than low values (skewed data).
A formal linear regression of platelet function will 
be carried with a robust error structure to allow for the 
multiple sampling points per participant. The robust 
error structure allows the calculation of SEs by dividing 
the SD by the root of the number of participants rather 
than the number of data points, so it does not over 
inflate the statistical significance for data which are not 
independent. This regression will allow us to quantify 
the difference in clotting risk for participants with and 
without cooling or participants with and without DAPT 
while controlling for the time the samples were taken.
Due to the small number of participants in this data set 
and the fact that it is not powered to detect differences 
the p values themselves will not be reported, but the CI 
around the effect sizes will be reported to allow for the 
planning of full definitive studies.
To establish the methodology for any future definitive 
work, the feasibility parameters for various methodolog-
ical issues will be described using 95% CIs. We will report 
the data needed to plan a future trial such as the 
percentage of eligible participants recruited to the trial, 
the percentage which failed to achieve adequate consent, 
the percentage of blood samples which did not yield 
useful results and the percentage of participants who 
had samples taken within 2 hours of the predefined time 
points.
To characterise the coagulation and platelet function in 
OHCA and STEMI participants we will tabulate the labo-
ratory results for each of these groups and separate the 
results by time for those in both of the cohorts. We will 
also tabulate the data separately for those receiving and 
not receiving DAPT at each time point. A further tabula-
tion will be made comparing the coagulation and platelet 
function in each group by type of DAPT delivered (clopi-
dogrel vs prasugrel vs ticagrelor). In each case, we will 
report mean, median, SD and range.
group.bmj.com on August 24, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5Skorko A, et al. BMJ Open 2017;7:e015663. doi:10.1136/bmjopen-2016-015663
Open Access
Given the non-interventional nature of this study a 
formal data management committee has not be formed. 
Instead the study trial committee will meet on a monthly 
basis during patient recruitment to review the recruit-
ment and safety reporting processes.
ethIcs and dIsseMInatIon
The study has been granted and will be carried out in 
accordance with Health Research Authority approval, 
encompassing Research Ethics Committee (REC) and 
local research and development approvals.
The enrolment of participants after cardiac arrest is 
ethically challenging and requires special consideration 
as regards consent. Conducting research in emergency 
situations where a patient lacks capacity is regulated by 
the Mental Capacity Act (2005) for England and Wales. 
The occurrence of a cardiac arrest out of hospital is 
unpredictable. Within seconds of cardiac arrest, a person 
becomes unconscious and thus incapacitated. As a result, 
it is impossible to obtain prospective consent from the 
individual. In this setting, it is also impractical to consult 
next of kin or an independent registered medical practi-
tioner without placing the potential participant at risk of 
harm from delaying treatment. Therefore, it is not prac-
tical to seek any form of consent before initial enrolment. 
Instead a model of deferred consent will be used when 
enrolling participants.
Consent will be sought from participants by an appro-
priately trained member of the research team to continue 
follow-up data collection as soon as the individual is 
able to give informed consent. However post-OHCA 
care necessitates the participant to be sedated for at 
least 72 hours, and therefore, the time until they regain 
capacity is greatly deferred.
Given this situation, initial advice about ongoing inclu-
sion in the study will be sought from a personal consultee 
(as identified by the participant’s clinical team). This 
consultee will be informed of the participant’s enrol-
ment in the study and their view sought as to whether the 
participant would have been willing to be involved, under 
the provisions of the Mental Capacity Act. The research 
team will liaise with clinical staff to determine the optimal 
time to make this approach, ideally within 24–96 hours 
of ICU admission. A full explanation of the purpose of 
the study, the protocol, interventions thus far and future 
interventions will be given. An information sheet will be 
provided. It will also be explained that once the partici-
pant regains capacity, they will be asked to give informed 
consent to continue in the study. Should the participant 
not wish to be involved their decision will override that 
given by the consultee.
If this personal consultee does not feel the participant 
would have agreed to enrolment, they will be withdrawn 
from the study. In this instance, additional advice will be 
sought as to whether the data and blood samples already 
collected may be retained or whether these should be 
destroyed.
If the personal consultee feels the participant would 
have agreed to enrolment, a written opinion will be 
obtained from this consultee and the participant will 
continue in the study.
In instances where no personal consultees are iden-
tified, a professional consultee will be sought from the 
lead clinician involved in the participant’s care. This indi-
vidual will be independent of the research team and be in 
no way associated with the study. It is envisaged that this 
approach will be made within 24–96 hours of admission 
to ICU.
Participants themselves will be approached for consent 
once they have recovered sufficiently from the OHCA and 
regained capacity, as judged by the clinical team respon-
sible for that participant’s care. If it is felt the participant 
does not have capacity to give informed consent every 
effort will still be made to explain the study to the indi-
vidual, in the presence of their personal consultee and an 
information leaflet left. This leaflet will include contact 
details for the research team should the individual have 
questions in the future.
If the participant does have capacity and does not 
consent, they will be withdrawn from the study, regardless 
of the earlier opinion of their personal consultee.
Finally, if no assent or consent can be obtained (eg, 
the participant dies and no appropriate consultee can be 
identified), then the participant will be withdrawn from 
the study and all data and blood samples relating to that 
individual will be destroyed.
Participants presenting with STEMI will be consented 
by a member of the research team as soon as clinically 
appropriate after arrival in the CCL prior to PCI. An 
assent model will be used whereby the individual is given 
a brief verbal description of the study and asked to state a 
preference. No formal capacity assessment is performed. 
If verbal assent is given, an independent witness is asked 
to sign a form. Once the participant has completed their 
acute treatment and had an opportunity to recuperate 
the research team will approach the patient again. During 
this visit, the study will be explained in detail, a patient 
information leaflet will be provided and written consent 
sought.
If an individual or consultee initially agrees to partici-
pation but later withdraws they will be asked to indicate 
whether they are willing for the information and samples 
collected thus far to be retained or for all these to be 
destroyed in a secure manner.
It will be made clear at the time of consent or assent 
that withdrawal can occur up to the point that the infor-
mation and samples become anonymised. Anonymisation 
will occur on the day of study completion; 30 days after 
the enrolment of the final participant. After this time, it 
is impossible to trace which samples or results belong to 
whom.
On completion of the study, data will be analysed as 
per the data analysis plan. Results will be submitted to 
appropriate peer-reviewed journals for publication and 
to national and international conferences. The results 
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will be presented to the local patient and public interest 
group who assisted with refining the protocol, along 
with staff at our institution. It is anticipated that anon-
ymous da125443125443ta will ultimately be deposited 
in an appropriate data repository. Despite anonymisa-
tion of the results, the potentially sensitive nature of the 
data means that it will be stored under an appropriately 
managed access process rather than a fully ‘open data’ 
arrangement and access restricted to researchers who 
have signed a data sharing agreement and gained appro-
priate ethics committee approvals. The final decision 
regarding data access will be made in conjunction with 
the publishing journal.
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